Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus UNIPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus UNIPEN.
BACTOCILL vs UNIPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic